Introduction
Multidrug resistance (MDR) of some human cancers, particularly acute myeloid leukemia (AML), remains a major obstacle to successful chemotherapy. The best characterized resistance mechanism in AML is the one mediated by the MDR1 gene. MDR1 gene expression has been extensively studied in AML and has been shown to be associated with poorer outcome. 1, 2 However, in several studies, 3, 4 in vitro drug resistance was observed in the absence of MDR1 phenotype. This suggests that alternative proteins, such as the more recently recognized multidrug resistance associated protein (MRP) 5 or the lung resistance protein (LRP) 6 may contribute to the MDR phenotype. The role of LRP in clinical MDR in AML is controversial. Two studies using immunocytochemistry (ICC) 7, 8 and one study using reverse-transcription polymerase chain reaction (RT-PCR) 9 showed correlation between LRP expression and treatment failure, but two using flow cytometry (FC) 10, 11 did not. In cell lines, LRP expression was associated not only with resistance to doxorubicin, as Pgp and MRP, but also to carboplatin, cisplatin and melphalan, 12 which are not extruded by Pgp or MRP. Therefore, the functionality of LRP could be estimated in cell lines by the in vitro resistance (MTT test) to cisplatin.
We therefore analyzed the correlations between the three techniques used with the 50% lethal concentration (LC 50 ) of cisplatin in cell lines. We also compared multiple assays (including RT-PCR, ICC and FC) in 10 cell lines and in 47 fresh and thawed AML cells in order to validate and to quantitate measures for the LRP phenotype detection. Lastly, we compared different ways to express the results by these different techniques.
Materials and methods

Cell lines
The present study used 10 cell lines with different levels of LRP expression: A549 (a gift from S Chevillard, Institut Curie, Paris, France), a lung adenocarcinoma expressing a spontaneously high level of MRP;K562, a human erythroleukemia (gift from BI Sickic, Stanford, CA, USA) and R7, a subline of K562 selected with 10 −6 mol/l of daunorubicin. The other cell lines were: HL60/DNR and HL60/DOX sublines of HL60 (human promyelocytic leukemia), resistant to daunorubicin (gift from F Lacombe, Bordeaux, France and F Calvo, Hô pital Saint-Louis, France, respectively); the T lymphoblastic cell lines CEM and CEM/VLB (gift from F Calvo) selected with 50 ng/ml of vinblastine; the breast carcinoma cell lines MCF7 and MCF7R selected with 10 −6 mol/l of daunorubicin. All cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mmol/l glutamine, 100 UI penicillin and 100 ng/ml streptomycin at 37°C in a humid atmosphere with 5% CO 2 . Exponentially growing cells were used for all experiments.
Patients and treatments
Forty-seven consecutive AML patients (37 de novo and 10 in relapse) were analyzed for LRP expression. Diagnosis was based on French-American-British (FAB) criteria. 13, 14 Immunophenotyping was performed by using flow cytometry. For each patient, several clinical and biological characteristics were analyzed (age, WBC at diagnosis, karyotype) and correlated with the level of LRP expression. Only de novo AML patients (37 patients) were analyzed for response to therapy. We analyzed, for these patients, the percentage of complete remission (CR) (two patients who died in aplasia were not included for this analysis), the disease-free survival (DFS) and the overall survival (OS) duration. Patients were included in the EORTC Leukemia Cooperative Group protocols, AML10 or AML13 for younger or older patients, respectively.
LRP mRNA expression measured by RT-PCR
Total RNA from cells (10 7 ) was extracted according to the acid guanidinium-phenol-chloroform technique. 15 cDNA was synthesized as described previously. 16 The resulting cDNA was stored at −20°C until used. The primers used were: 5Ј-ACA ACT ACT GCG TGA TTC TC-3Ј (LRP sense strand) and 5Ј-TCA GCA TGT AGG TGC TTC CA-3Ј (LRP antisense strand). They amplified a 390 bp LRP fragment corresponding to nucleotides 941 to 1330 of the LRP cDNA sequence. 17 The specificity of these primers was proved by the fact that there was no non-specific band amplified by PCR. PCR was carried out as described previously. 18 The achieved reaction mixture was heated at 95°C for 3 min. Amplification was performed in sequential cycles of 95°C 30 s, 53°C 30 s and 72°C 45 s. After 28 cycles of amplification, all samples were incubated for an additional 8 min at 72°C. The variations between samples in the cDNA synthesis were normalized by their relative quantities of ␤2m amplified by 23 cycles PCR. The normalized yield of LRP products relative to ␤2m were then compared to those of A549 cells, which were defined as 1 arbitrary unit. No arbitrary minimal cut-off points were used in data analysis, in accordance with several consensus recommendations.
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LRP protein expression measured by flow cytometry
Cells were permeabilized for 15 min in 15% (v/v) lysing solution G (Becton Dickinson, Pont de Claye, France) in H 2 O and incubated for 15 min in PBS/BSA containing 1% (v/v) normal goat serum. Cells (5 × 10 5 ) were incubated for 1 h at 4°C in 100 l PSB/BSA 5% containing either the monoclonal antibody (MAbs) LRP-56 (2 g/ml) (IgG2b) (a gift from RJ Scheper, Amsterdam, The Netherlands) or the mouse isotype-matched control MAbs (Immunotech, Marseille, France). Antibody binding was detected with R-phycoerythrin-labelled goat antimouse immunoglobulins (Immunotech) in accordance with the consensus recommendations of Beck et al. 19 Fluorescence was analyzed on a FACSort flow cytometer (Becton Dickinson). For each sample, 5000 events were collected. The expression of LRP was checked on selected cells by CD34 antibody (HPCA 2 clone; Becton Dickinson) (two-color assays) or other markers (for examples CD33/CD7, CD33/CD2, CD33/CD19 or CD33/CD22 by three-color assays) (all these antibodies, Becton Dickinson) if possible, or with physical characteristics only if blast cells had no characteristic marker. LRP protein value was expressed by two methods: first, as adjusted for control, ie as ratio of arithmetic mean fluorescence of LRP-56/IgG2b control; second, protein staining of gated leukemic blasts was compared with one of the control cells by means of the Kolmorogov-Smirnov (KS) test. This statistic, denoted D, measures the difference between two distribution functions and generates a value ranging from −1.0 to 1.0. These two methods accurately identify small differences in fluorescence and are useful in detection of low level protein expression, which frequently occurs in patient samples. 3 LRP protein expression was reported as a continuous variable in accordance with the several consensual recommendations for MDR1 expression.
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LRP protein expression measured by immunocytochemistry
LRP expression was determined by an alkaline phosphatase immunocytochemical detection method 22 using the specific monoclonal antibody (MoAb) LRP-56. Cytospins were prepared by centrifugation of 50 l cell suspension (0.2 × 10 6 cells/ml TBS containing 5% human serum albumin) at 50 g for 4 min. Cytospins were air-dried for at least 24 h and stored at −20°C. Cells were fixed using methanol at −20°C for 5 min then using 0.25% Triton X-100 for 5 min at room temperature. For immunocytochemical detection of LRP protein, the alkaline phosphatase-labelled avidin-biotin method was used (Dako, LSAD kit). All incubations were performed in a humidifier. After each incubation, cells were washed twice in TBS. Cells were incubated with primary antibody (LRP-56, 0.5 g/ml) or with idiotype-matched control (nonspecific mouse IgG2b, 0.5 g/ml; Immunotech) for 3 h at 37°C, followed by incubation with biotinylated rabbit anti-mouse (1/150 dilution; Dako, Trappes, France) for 20 min. Subsequently, antibody binding was detected by the streptavidinbiotin-alkalin phosphatase method. Finally, cells were counterstained using hematoxylin solution. The staining of cells was examined using a light microscope. Staining of at least 200 cells was evaluated and scored. The degree of expression was expressed according to (1) the percentage of stained leukemic cells; and (2) the intensity of antibody staining (reported as negative (−), low (+), intermediate (++) and high (+++)) ( Figure 1) . However, the intensity of antibody staining was not identical for all cells for the same patient ( Figure 2 ). Therefore, we also used a third scoring system (score system): for each cell we determined the intensity of LRP-56 staining (reported as negative (0), low (1), intermediate (2) and high (3). We evaluated 200 cells and the total score was divided by 200. As recommended by different consensus for MDR1 expression, arbitrary minimal cut-off points were not used in data analysis.
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In vitro cisplatin sensitivity using MTT assay Sensitivity of cells to cisplatin was determined by planting 4 × 10 4 cells in 200 ml growth medium containing three-fold serial dilutions of the drug in 96-well microtiter plates. Each concentration of drugs was repeated in six wells. After incubation for 3 days at 37°C with 5% CO 2 , cell viability was determined using the MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) (Sigma, Grenoble, France) assay as described by Plumb et al. 23 Briefly, 20 l of MTT (5 mg/ml in PBS) was added to each well and incubated for 6 h. The medium and MTT were then removed from the wells after centrifugation, and formazan crystals were dissolved in 200 l of DMSO. The absorbance was recorded in a microplate reader (Model MR5000; Dynatech Laboratories, France) at the wavelength of 550 nm. The effect of drug on growth inhibition could be assessed as: % of growth inhibition = 1 − [(absorbance of drug treated cells/absorbance of untreated cells) × 100]. The LC 50 was determined as the drug concentration which resulted in a 50% of growth inhibition.
Statistical methods
Clinical and biological factors were investigated for their influence on remission rate by the 2 or Fisher's exact tests for binary variables and by the Mann-Whitney U test or KruskalWallis tests for continuous values. Correlations among levels of expression of continuous values were estimated using the Spearman rank coefficient. The rates of DFS and survival were estimated by the method of Kaplan and Meier 24 and compared by log-rank tests. Tests for comparison were regarded as significant if the two-sided P value was less than 0.05.
Results
Results for 10 cell lines
For LRP expression, there was a correlation between FC and ICC (r = 0.78, P = 0.01 using the score system for ICC and r = 0.76, P = 0.02 using the percentage of positive cells) but no correlation between RT-PCR and FC (r = 0.39, P = 0.38) and between RT-PCR and ICC (r = 0.64, P = 0.11 using the score system and r = 0.70, P = 0.08, using the percentage of positive cells). We have also analyzed the level of LC 50 of cisplatin in these different cell lines. There was a good correlation between the LC 50 of cisplatin and LRP expression measured by FC (r = 0.94, P Ͻ 0.0001), a correlation between LC 50 of cisplatin and LRP expression measured by ICC (r = 0.81, P = 0.004 using the score system and r = 0.80, P = 0.005 using the percentage of positive cells) and no correlation between LC 50 of cisplatin and LRP expression measured by RT-PCR (r = 0.44, P = 0.32) (Figure 3) .
LRP expression by RT-PCR and LRP-56 staining by ICC and FC in 47 AML cells
Twenty-one patients were tested twice for RT-PCR on the same frozen cells; the reproducibility of the level of LRP
Figure 3
Correlations between LC 50 of cisplatin with (a) LPR expression measured by RT-PCR; (b) LRP expression measured by ICC (using score system) and (c) LRP expression measured by FC (using ratio of mean fluorescence). expression was good (r = 0.94, P Ͻ 0.0001) (Figure 4 ). When ICC was used, we collected three types of data: (1) the intensity of LRP-56 staining; (2) the percentage of LRP-positive cells; and (3) the score system. The correlations between these data were high (r = 0.87, P Ͻ 0.0001, between (1) and (2); r = 0.68, P Ͻ 0.0001 between (1) and (3); r = 0.73, P Ͻ 0.0001 between (2) and (3)). Thirteen patients were tested twice for ICC on the same cells; the correlations were also good (r = 0.88, P = 0.003, measuring the intensity of antibody staining and r = 0.88, P = 0.003, measuring the percentage of positive cells, (Figure 4) and r = 0.80, P = 0.009 measuring by the score system). When FC was used, protein values were expressed by two methods: first as the ratio of arithmetic mean fluorescence LRP-56/IgG2b control; second, LRP-56 staining was compared with control cells by the Kolmorogov-Smirnov test. These two methods were correlated (r = 0.83, P Ͻ 0.0001). When LRP56 staining was measured by FC, there was also a high correlation between fresh and thawed AML samples (r = 0.83, P = 0.002) (Figure 4 ).
Correlation between three techniques used
Between the three methods used, there was only a weak cor- relation between FC and ICC (r = 0.45, P = 0.03), no correlation between RT-PCR and ICC (r = 0.22, P = 0.15) and no correlation between RT/PCR and FC (r = 0.30, P = 0.08). The percentage of negative patients was higher by FC (23%) and ICC (30%) than by RT-PCR (9%) ( Table 1 ). All negative patients by RT-PCR were negative by ICC and FC, but six positive patients by RT-PCR were negative by ICC and FC and five positive patients by RT-PCR were negative either by FC or ICC. Therefore, there was a dissociation between ICC and FC for five patients. All these patients, except one, were positive by FC and negative by ICC (Table 1) .
Correlation with clinical data
There was no significant effect of previous therapy (patients in relapse) on the level of LRP expression (measured by RT-PCR, ICC and FC) ( Table 2 ). The level of LRP expression measured by RT-PCR was not significantly associated with age, WBC at diagnosis, cytogenetic and FAB subtype ( Table 2) . LRP gene expression measured by ICC and FC was significantly higher in patients у60 years old than in patients Ͻ60 years ( Table 2) . Cytogenetics with good prognosis was significantly associated with the low level of LRP expression measured by FC, but not as measured by ICC (Table 2) .
LRP expression and patients outcome
The level of LRP gene expression, measured by RT-PCR, ICC and FC, was not a prognostic factor for achievement of CR (Table 3) or DFS duration. OS duration was influenced by the level of LRP-56 staining measured by ICC (P = 0.02 using the percentage of positive cells; P = 0.02 using the intensity of LRP-56 staining; and P = 0.18 using the score system). Inversely, OS duration was not influenced by the level of LRP expression as measured by RT-PCR (P = 0.99) or FC (P = 0.47 as measured by the ratio of mean fluorescence and P = 0.58, as measured by the KS test) ( Figure 5 ).
Discussion
The aim of this study was to contribute to the standardization of LRP detection methods in AML. The role of LRP in clinical MDR in AML is controversial (Table 4) . We therefore compared multiple assays (including RT-PCR, ICC and FC) in 10 cell lines and 47 fresh and thawed adult AML. In our study, the reproducibility of LRP detection measured by RT-PCR, ICC and FC was good. In the same way, there was good correlation between the two methods expressing the results of LRP detection by FC, and between the three methods expressing LRP detection by ICC. Therefore, the discrepancies noted with the three techniques used in the literature (RT-PCR, ICC and FC) were neither a problem of reproducibility of experience nor a problem of results expression. There was no correlation between LRP expression measured by RT-PCR and LRP protein detection techniques measured by ICC and FC. The absence of correlation between RT-PCR and other methods for LRP protein detection, even though LRP level measured by this technique is reproducible, may be explained by a posttranscriptional regulation, given that major vault protein are multi-unit protein structures. 6 In AML cells, all negative patients (for LRP expression) by RT-PCR were negative by ICC and FC, and six positive patients by RT-PCR were negative by ICC and FC. These facts may confirm the hypothesis of a posttranscriptional regulation of LRP expression. Therefore, RT-PCR is probably not the best technique for LRP detection if the aim of a study is the role of LRP in resistance to chemotherapy.
On the other hand, there was only weak correlation between ICC and FC in 47 AML cells and 10 cell lines. In another study, 12 there was an association between LRP expression and resistance to cisplatin in cell lines, a drug not dependent of Pgp or MRP. Therefore the functionality of LRP could be estimated in cell lines by the in vitro resistance to cisplatin. In these cell lines we have shown a higher correlation between FC and LC 50 of cisplatin than between ICC and LC 50 of cisplatin, and no correlation between RT-PCR and LC 50 of cisplatin. In five patients, there was a dissociation between ICC and FC. Four patients were positive by FC and negative by ICC and only one patient was negative by FC and positive by ICC. All these observations may explain the discrepancies observed between several studies using different techniques. [7] [8] [9] [10] [11] Therefore, if in vitro resistance to cisplatin represents the functionality of LRP, we recommend the use of FC rather than ICC to detect LRP expression. Besides the measurement of LRP as a diagnostic tool in the evaluation of resistance to chemotherapy in patients with AML, we urgently need to establish a functional test in order to assess LRP activity.
In our study, high expression of LRP was not a prognostic factor for achievement of CR or for the duration of DFS, as measured by RT-PCR, ICC and FC. As in other studies, high LRP expression was a prognostic factor for the duration of OS by ICC, 7, 8 but not by FC. 10, 11 High level of LRP measured by ICC was a prognostic factor for duration of overall survival but not for achievement of CR or for duration of CR; this difference was closely connected with death in aplasia (which was not included in achievement of CR or duration of CR in our study), but not with resistance disease. The level of LRP expression measured by ICC and FC, but not by RT-PCR, was correlated with poor prognostic factors in AML, such as age and karyotype, but independent of WBC count and previous chemotherapy.
In conclusion, (1) the three methods to determine LRP expression often yield discordant results; (2) RT-PCR is not recommended because of its lack of correlation with ICC and FC; (3) we recommend the detection of LRP by FC rather than by ICC; and (4) we urgently need a functional test to assess the LRP activity.
